Inventor, Thinking Outside The Box

THINKING OUTSIDE THE BOX IS AS SIMPLE AS ACCUMULATING WHAT WE ARE TAUGHT AND NOT WHAT WE THOUGHT WE WERE TAUGHT IN ORDER TO HELP OTHERS


Comments and Statements Are Simply A Portion Of The Thoughts and Theories Accumulated and Involved While Developing ArNeu.

At No Time Should The Comments and Statements Pertaining To ArNeu Be Considered As Directing Towards A Diagnosis, Treatment, Prevent or Cure, As Defined By FDA Definitions.  It Has Recently Been Brought To Our Attention That Some Individuals and Groups Define Treatment As The Relief Of Pain, But It Is Our Understanding That Treatment Is A Process Of Stopping A Disease Process And That The Relief Of Pain Symptoms Due To A Disease Is Just That, Temporary Pain Relief.  The Temporary Relief Of Pain Symptoms Is Very Beneficial Until A Cure Of A Disease Occurs, When Addressing Muscle & Joint Pain Symptoms.  Prevention Is Described As The Prevention Of A Disease, Not The Prevention Of A Pain Symptom.  

REMEMBER WHEN REVIEWING ALL MATERIALS: † These statements have not been evaluated by the Food and Drug Administration.  This product is not intended to diagnose, treat, cure, or prevent any disease, or implied.

CONSIDERATIONS WHILE DEVELOPING ArNeu:

1)  WHY DO PRODUCTS PERFORM DIFFERENTLY, WHEN THEY HAVE THE SAME AMOUNT OF ACTIVE INGREDIENTS:
a.  May be the theory that active ingredients becoming systemic have less value than perceived.  For example if menthol is relieving pain systemically through the blocking of signals through the lamina then why isn’t the pain relieved in other areas proximal to where a topical analgesic is applied
b.  Why do two different brands of pain relievers having the same ingredients perform so differently
c.  Reports of comparable products one non-generic and generic have different results when it comes to prescription
d.  Need Better, High Quality Ingredients
e.  Need better manufacturing processes
f.  Sacrifice high returns small quantity for low returns high quantity to bring a better product to those in pain

2) TECHNOLOGY IMPROVEMENTS THAT MAY BE USED TO MEASURE PERFORMANCE:
a.  Thermal images to view circulatory blockage, edema, swelling, inflammation, increased circulation and other valuable variable measurements
b.  Range of motion for muscular and joint movements digital angle measurements, photography, past performance records
c.  Voltmeters and computer download programs to monitor and compare products and ingredient activities
d. Overall information availability pertaining to clinical and scientific studies
d.  Technology has changed drastically since the original description of mechanisms of active ingredients

3)  NERVE FIBER INVOLVEMENT PERTAINING TO PAIN SYMPTOMS DUE TO VARIOUS DISEASES AND INJURIES:
a.  Nerve signals travel two directions
b.  Nerve signals stimulate vascular smooth muscles
c.  Perceived definition of neuropathy: The pressure put on nerves within muscle and joints that is developed by the inflammatory process and compounded by the inadequate removal of toxins in the vicinity that may result in further development of inflammation
d.  Could stimulation of nerve function provide better pain relief than decreasing nerve activity

4)  PROBABLE RESULTS OF RAPID INCREASED CIRCULATION:
a.  Redness might occur due to the movement of toxins and spent nutrients that develop when edema or swelling is present
b.  Itching sensation that might occur with the increase of toxin and spent nutrient movements

5)  PROBABLE RESULTS OF REDUCING EDEMA & SWELLING
a.  Less morning and daily stiffness.
b.  Increased joint motion
c.  Decreased fatigue
d.  Increased productivity

6)  PROBABLE BENEFITS OF REDUCED PAIN SENSATIONS:
a.  Lessen sleep deprivation
b.  Less mental depression
c.  Increased mental productivity
d.  Increased physical activity & productivity
e.  Decreased probability of suspending or delaying other needed therapies and treatments
f.  Better outlook on life and the future